Anthropic’s newly launched Bay Area wet lab, operating at BSL-1 and BSL-2 levels without human pathogens, drives the low market-implied odds for a confirmed pathogen escape. The facility’s first major output—a novel enzyme system akin to CRISPR, uncovered autonomously by Claude agents in September 2026—highlights controlled AI-assisted biology work with human scientists handling all physical experiments. Recent threat reports detail blocked misuse attempts for bioweapons research and model distillation by external labs, but no incidents of internal containment failure. Traders price the risk near 3% through year-end because strict protocols, limited pathogen scope, and rapid disclosure norms make an undetected or unconfirmed leak unlikely, though any expansion into higher-risk agents could shift sentiment.